221 related articles for article (PubMed ID: 23116124)
1. Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.
Yuan Y; Elbegdorj O; Chen J; Akubathini SK; Zhang F; Stevens DL; Beletskaya IO; Scoggins KL; Zhang Z; Gerk PM; Selley DE; Akbarali HI; Dewey WL; Zhang Y
J Med Chem; 2012 Nov; 55(22):10118-29. PubMed ID: 23116124
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.
Zheng Y; Obeng S; Wang H; Jali AM; Peddibhotla B; Williams DA; Zou C; Stevens DL; Dewey WL; Akbarali HI; Selley DE; Zhang Y
J Med Chem; 2019 Jan; 62(2):561-574. PubMed ID: 30608693
[TBL] [Abstract][Full Text] [Related]
3. Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.
Yuan Y; Elbegdorj O; Chen J; Akubathini SK; Beletskaya IO; Selley DE; Zhang Y
Bioorg Med Chem Lett; 2011 Sep; 21(18):5625-9. PubMed ID: 21788135
[TBL] [Abstract][Full Text] [Related]
4. Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.
Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Mosier PD; Kellogg GE; Dewey WL; Selley DE; Zhang Y
Bioorg Med Chem; 2015 Apr; 23(8):1701-15. PubMed ID: 25783191
[TBL] [Abstract][Full Text] [Related]
5. Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.
Zhang Y; Braithwaite A; Yuan Y; Streicher JM; Bilsky EJ
Eur J Pharmacol; 2014 Aug; 736():124-30. PubMed ID: 24815322
[TBL] [Abstract][Full Text] [Related]
6. 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.
Zhang Y; Williams DA; Zaidi SA; Yuan Y; Braithwaite A; Bilsky EJ; Dewey WL; Akbarali HI; Streicher JM; Selley DE
ACS Chem Neurosci; 2016 Mar; 7(3):297-304. PubMed ID: 26716358
[TBL] [Abstract][Full Text] [Related]
7. Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function.
Yuan Y; Elbegdorj O; Beletskaya IO; Selley DE; Zhang Y
Bioorg Med Chem Lett; 2013 Sep; 23(18):5045-8. PubMed ID: 23948248
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
Li G; Aschenbach LC; Chen J; Cassidy MP; Stevens DL; Gabra BH; Selley DE; Dewey WL; Westkaemper RB; Zhang Y
J Med Chem; 2009 Mar; 52(5):1416-27. PubMed ID: 19199782
[TBL] [Abstract][Full Text] [Related]
9. Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.
Obeng S; Jali A; Zheng Y; Wang H; Schwienteck KL; Chen C; Stevens DL; Akbarali HI; Dewey WL; Banks ML; Liu-Chen LY; Selley DE; Zhang Y
ACS Chem Neurosci; 2019 May; 10(5):2518-2532. PubMed ID: 30758946
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Biological Evaluation of NAP Isosteres: A Switch from Peripheral to Central Nervous System Acting Mu-Opioid Receptor Antagonists.
Pagare PP; Li M; Zheng Y; Kulkarni AS; Obeng S; Huang B; Ruiz C; Gillespie JC; Mendez RE; Stevens DL; Poklis JL; Halquist MS; Dewey WL; Selley DE; Zhang Y
J Med Chem; 2022 Mar; 65(6):5095-5112. PubMed ID: 35255685
[TBL] [Abstract][Full Text] [Related]
11. Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.
Mitra P; Venitz J; Yuan Y; Zhang Y; Gerk PM
Drug Metab Dispos; 2011 Sep; 39(9):1589-96. PubMed ID: 21685245
[TBL] [Abstract][Full Text] [Related]
12. Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible μ opioid receptor antagonist effects.
Moynihan HA; Derrick I; Broadbear JH; Greedy BM; Aceto MD; Harris LS; Purington LC; Thomas MP; Woods JH; Traynor JR; Husbands SM; Lewis JW
J Med Chem; 2012 Nov; 55(22):9868-74. PubMed ID: 23043264
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder.
Zheng Y; Obeng S; Reinecke BA; Chen C; Phansalkar PS; Walentiny DM; Gerk PM; Liu-Chen LY; Selley DE; Beardsley PM; Zhang Y
Eur J Pharmacol; 2019 Dec; 865():172812. PubMed ID: 31743739
[TBL] [Abstract][Full Text] [Related]
14. Nanoconjugated NAP as a Potent and Periphery Selective Mu Opioid Receptor Modulator To Treat Opioid-Induced Constipation.
Xu GG; Zolotarskaya OY; Williams DA; Yuan Y; Selley DE; Dewey WL; Akbarali HI; Yang H; Zhang Y
ACS Med Chem Lett; 2017 Jan; 8(1):78-83. PubMed ID: 28105279
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of TAN-452, a novel peripherally acting opioid receptor antagonist for the treatment of opioid-induced bowel syndromes.
Suzuki T; Sawada T; Kawai K; Ishihara Y
Life Sci; 2018 Dec; 215():246-252. PubMed ID: 30036489
[TBL] [Abstract][Full Text] [Related]
16. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
Mizoguchi H; Hung KC; Leitermann R; Narita M; Nagase H; Suzuki T; Tseng LF
Eur J Pharmacol; 2003 Feb; 461(1):35-9. PubMed ID: 12568913
[TBL] [Abstract][Full Text] [Related]
17. Rational Design, Chemical Syntheses, and Biological Evaluations of Peripherally Selective Mu Opioid Receptor Ligands as Potential Opioid Induced Constipation Treatment.
Huang B; Li M; Klongkumnuankarn P; Mendez RE; Gillespie JC; Stevens DL; Dewey WL; Selley DE; Zhang Y
J Med Chem; 2022 Mar; 65(6):4991-5003. PubMed ID: 35255683
[TBL] [Abstract][Full Text] [Related]
18. 14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists.
Nieland NP; Rennison D; Broadbear JH; Purington L; Woods JH; Traynor JR; Lewis JW; Husbands SM
J Med Chem; 2009 Nov; 52(21):6926-30. PubMed ID: 19842669
[TBL] [Abstract][Full Text] [Related]
19. Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators.
Ma H; Obeng S; Wang H; Zheng Y; Li M; Jali AM; Stevens DL; Dewey WL; Selley DE; Zhang Y
J Med Chem; 2019 Dec; 62(24):11399-11415. PubMed ID: 31782922
[TBL] [Abstract][Full Text] [Related]
20. Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.
Yuan Y; Li G; He H; Stevens DL; Kozak P; Scoggins KL; Mitra P; Gerk PM; Selley DE; Dewey WL; Zhang Y
ACS Chem Neurosci; 2011 Jul; 2(7):346-51. PubMed ID: 22816021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
